Yuan, J. et al. Novel applied sciences and rising biomarkers for personalised most cancers immunotherapy. J. Immunother. Most cancers 4, 3 (2016).
Connors, J. et al. Utilizing the facility of innate immunoprofiling to grasp vaccine design, an infection, and immunity. Hum. Vaccines Immunother. 19, 2267295 (2023).
Ogunniyi, A. O. et al. Profiling human antibody responses by built-in single-cell evaluation. Vaccine 32, 2866–2873 (2014).
Stork, E. M. et al. Antigen-specific Fab profiling achieves molecular-resolution evaluation of human autoantibody repertoires in rheumatoid arthritis. Nat. Commun. 15, 3114 (2024).
Lu, R. M. et al. Growth of therapeutic antibodies for the remedy of ailments. J. Biomed. Sci. 27, 1 (2020).
Deshaies, R. J. Multispecific medicine herald a brand new period of biopharmaceutical innovation. Nature 580, 329–338 (2020).
Zhong, X., D’antona, A. M., Karagiannis, S. & White, A. Current advances within the molecular design and functions of multispecific biotherapeutics. Antibodies 10, 13 (2021).
Weiner, G. J. Constructing higher monoclonal antibody-based therapeutics. Nat. Rev. Most cancers 15, 361–370 (2015).
Gérard, A. et al. Excessive-throughput single-cell activity-based screening and sequencing of antibodies utilizing droplet microfluidics. Nat. Biotechnol. 38, 715–721 (2020).
Muruato, A. E. et al. A high-throughput neutralizing antibody assay for COVID-19 prognosis and vaccine analysis. Nat. Commun. 11, 4059 (2020).
Tickle, S. et al. Excessive-throughput screening for prime affinity antibodies. J. Lab. Autom. 14, 303–307 (2009).
Schofield, D. J. et al. Utility of phage show to excessive throughput antibody technology and characterization. Genome Biol. 8, R254 (2007).
Carlson, E. D., Gan, R., Hodgman, C. E. & Jewett, M. C. Cell-free protein synthesis: functions come of age. Biotechnol. Adv. 30, 1185–1194 (2012).
Cubillos-Ruiz, A. et al. Engineering dwelling therapeutics with artificial biology. Nat. Rev. Drug Discov. 20, 941–960 (2021).
Gu, Y. et al. Cell-free protein synthesis system for bioanalysis: advances in strategies and functions. Developments Anal. Chem. 161, 117015 (2023).
Slomovic, S., Pardee, Okay. & Collins, J. J. Artificial biology units for in vitro and in vivo diagnostics. Proc. Natl Acad. Sci. USA 112, 14429–14435 (2015).
Murray, C. J. & Baliga, R. Cell-free translation of peptides and proteins:from excessive throughput screening to medical manufacturing. Curr. Opin. Chem. Biol. 17, 420–426 (2013).
Ramm, F. et al. Mammalian cell-free protein expression promotes the purposeful characterization of the tripartite non-hemolytic enterotoxin from Bacillus cereus. Sci. Rep. 10, 2887 (2020).
Thoring, L. et al. Cell-free programs primarily based on CHO cell lysates: optimization methods, synthesis of “difficult-to-express” proteins and future views. PLoS ONE 11, e0163670 (2016).
Garenne, D., Bowden, S. & Noireaux, V. Cell-free expression and synthesis of viruses and bacteriophages: functions to drugs and nanotechnology. Curr. Opin. Syst. Biol. 28, 100373 (2021).
Sullivan, C. J. et al. A cell-free expression and purification course of for fast manufacturing of protein biologics. Biotechnol. J. 11, 238–248 (2016).
Pardee, Okay. et al. Fast, low-cost detection of Zika virus utilizing programmable biomolecular elements. Cell 165, 1255–1266 (2016).
Silverman, A. D., Akova, U., Alam, Okay. Okay., Jewett, M. C. & Lucks, J. B. Design and optimization of a cell-free atrazine biosensor. ACS Synth. Biol. 9, 671–677 (2020).
Wen, Okay. Y. et al. A cell-free biosensor for detecting quorum sensing molecules in P. aeruginosa-infected respiratory samples. ACS Synth. Biol. 6, 2293–2301 (2017).
Hunt, A. C. et al. A fast cell-free expression and screening platform for antibody discovery. Nat. Commun. 14, 3897 (2023).
Ojima-Kato, T., Nagai, S. & Nakano, H. Ecobody expertise: fast monoclonal antibody screening methodology from single B cells utilizing cell-free protein synthesis for antigen-binding fragment formation. Sci. Rep. 7, 13979 (2017).
Stech, M. & Kubick, S. Cell-free synthesis meets antibody manufacturing: a overview. Antibodies 4, 12–33 (2015).
Ramachandran, N. et al. Self-assembling protein microarrays. Science 305, 86–90 (2004).
Gerber, D., Maerkl, S. J. & Quake, S. R. An in vitro microfluidic method to producing protein-interaction networks. Nat. Strategies 6, 71–74 (2009).
Blackburn, M. C., Petrova, E., Correia, B. E. & Maerkl, S. J. Integrating gene synthesis and microfluidic protein evaluation for fast protein engineering. Nucleic Acids Res. 44, e68 (2015).
Markin, C. J. et al. Revealing enzyme purposeful structure through high-throughput microfluidic enzyme kinetics. Science 373, eabf8761 (2021).
Norouzi, M. et al. Cell-free dot blot: an ultra-low-cost and sensible immunoassay platform for detection of anti-SARS-CoV-2 antibodies in human and animal sera. Microbiol. Spectr. 11, e0245722 (2023).
Hufnagel, Okay. et al. In situ, cell-free protein expression on microarrays and their use for the detection of immune responses. Bio-protocol 9, e3152 (2019).
Goshima, N. et al. Human protein manufacturing facility for changing the transcriptome into an in vitro-expressed proteome. Nat. Strategies 5, 1011–1017 (2008).
Morishita, R. et al. CF-PA2Vtech: a cell-free human protein array expertise for antibody validation towards human proteins. Sci. Rep. 9, 19349 (2019).
Levy, M., Falkovich, R., Daube, S. S. & Bar-Ziv, R. H. Autonomous synthesis and meeting of a ribosomal subunit on a chip. Sci. Adv. 6, eaaz6020 (2020).
Vonshak, O. et al. Programming multi-protein meeting by gene-brush patterns and two-dimensional compartment geometry. Nat. Nanotechnol. 15, 783–791 (2020).
Buxboim, A. et al. A single-step photolithographic interface for cell-free gene expression and lively biochips. Small 3, 500–510 (2007).
Bracha, D. et al. Entropy-driven collective interactions in DNA brushes on a biochip. Proc. Natl Acad. Sci. USA 110, 4534–4538 (2013).
Förste, S. et al. Computational evaluation of protein synthesis, diffusion, and binding in compartmental biochips. Microb. Cell Reality. 22, 244 (2023).
Buxboim, A., Daube, S. S. & Bar-Ziv, R. Artificial gene brushes: a construction–operate relationship. Mol. Syst. Biol. 4, 181 (2008).
Caschera, F. & Noireaux, V. Synthesis of two.3 mg/ml of protein with an all Escherichia coli cell-free transcription–translation system. Biochimie 99, 162–168 (2014).
Zhang, S., Garcia-D’Angeli, A., Brennan, J. P. & Huo, Q. Predicting detection limits of enzyme-linked immunosorbent assay (ELISA) and bioanalytical methods usually. Analyst 139, 439–445 (2013).
Seydoux, E. et al. Evaluation of a SARS-CoV-2-infected particular person reveals improvement of potent neutralizing antibodies with restricted somatic mutation. Immunity 53, 98–105.e5 (2020).
Ter Meulen, J. et al. Human monoclonal antibody mixture towards SARS coronavirus: synergy and protection of escape mutants. PLoS Med. 3, 1071–1079 (2006).
Gong, Y., Qin, S. & Dai, L. The glycosylation in SARS-CoV-2 and its receptor ACE2. Sign Transduct. Goal. Ther. 6, 396 (2021).
Telenti, A., Hodcroft, E. B. & Robertson, D. L. The evolution and biology of SARS-CoV-2 variants. Chilly Spring Harb. Perspect. Med. 12, a041390 (2022).
Huang, M. et al. Atlas of at present obtainable human neutralizing antibodies towards SARS-CoV-2 and escape. Immunity 55, 1501–1514 (2022).
Lee, C. H. et al. Potential CD8+ T cell cross-reactivity towards SARS-CoV-2 conferred by different coronavirus strains. Entrance. Immunol. 11, 579480 (2020).
Wu, W., Cheng, Y., Zhou, H., Solar, C. & Zhang, S. The SARS-CoV-2 nucleocapsid protein: its position within the viral life cycle, construction and capabilities, and use as a possible goal within the improvement of vaccines and diagnostics. Virol. J. 20, 6 (2023).
Movsisyan, M. et al. Monitoring the evolution of anti-SARS-CoV-2 antibodies and long-term humoral immunity inside 2 years after COVID-19 an infection. Sci. Rep. 14, 13417 (2024).
Kightlinger, W. et al. A cell-free biosynthesis platform for modular development of protein glycosylation pathways. Nat. Commun. 10, 5404 (2019).
Marani, M., Katul, G. G., Pan, W. Okay. & Parolari, A. J. Depth and frequency of utmost novel epidemics. Proc. Natl Acad. Sci. USA 118, e2105482118 (2021).
Hurlburt, N. Okay. et al. Structural foundation for potent neutralization of SARS-CoV-2 and position of antibody affinity maturation. Nat. Commun. 11, 5413 (2020).
Gibson, D. G. et al. Enzymatic meeting of DNA molecules as much as a number of hundred kilobases. Nat. Strategies 6, 343–345 (2009).
Buxboim, A., Daube, S. S. & Bar-Ziv, R. Ultradense artificial gene brushes on a chip. Nano Lett. 9, 909–913 (2009).
Garamella, J., Marshall, R., Rustad, M. & Noireaux, V. The all E. coli TX-TL Toolbox 2.0: a platform for cell-free artificial biology. ACS Synth. Biol. 5, 344–355 (2016).
He, B. et al. Fast mutagenesis and purification of phage RNA polymerases. Protein Expr. Purif. 9, 142–151 (1997).
Yu, T., Laird, J. R., Prescher, J. A. & Thorpe, C. Gaussia princeps luciferase: a bioluminescent substrate for oxidative protein folding. Protein Sci. 27, 1509–1517 (2018).
Dupin, A. Cell-free immuno-profiling on a genetically programmed biochip. Zenodo https://doi.org/10.5281/zenodo.17151196 (2025).